This Under The Radar Fintech Company Congress Men and Hedge Funds are Loading up on

In partnership with

Top investors are buying this “unlisted” stock

When the team that co-founded Zillow and grew it into a $16B real estate leader starts a new company, investors notice. That’s why top firms like SoftBank invested in Pacaso.

Disrupting the real estate industry once again, Pacaso’s streamlined platform offers co-ownership of premier properties – revamping a $1.3T market.

By handing keys to 2,000+ happy homeowners, Pacaso has already made $110m+ in gross profits.

Now, after 41% gross profit growth last year, they recently reserved the Nasdaq ticker PCSO. But the real opportunity is now, at the unlisted stage.

Until May 29, you can join Pacaso as an investor for just $2.80/share.

Invest before the window closes.

_{This is a paid advertisement for Pacaso’s Regulation A offering. Please read the offering circular at invest.pacaso.com. Reserving a ticker symbol is not a guarantee that the company will go public. Listing on the NASDAQ is subject to approvals. Under Regulation A+, a company has the ability to change its share price by up to 20%, without requalifying the offering with the SEC.}

CompoSecure (CMPO) is one of those under-the-radar fintech plays that’s suddenly getting a lot of attention—not just from Wall Street, but from some big names in politics and the hedge fund world. Let’s break down what’s going on with this stock, why it’s catching eyes, and whether it might deserve a spot on your watchlist.

What’s CompoSecure All About?

CompoSecure is best known for making high-end metal payment cards—the kind you flash to impress at dinner—and it’s also got a digital authentication business called Arculus. The company’s been steadily growing its international footprint, and its Arculus segment is starting to show real promise as more people and businesses get serious about digital security.

The Numbers: Recent Performance

• Stock Price: Lately, CMPO has been trading in the $12–$14 range, not far off its 52-week high.

• Market Cap: About $1.38 billion, so it’s not a micro-cap gamble.

• Revenue: The company pulled in around $376 million over the last year.

• Profitability: It’s not profitable yet, with a recent net loss, but the trend is improving as the business scales.

• Analyst Sentiment: Wall Street is bullish—most analysts rate it a “Strong Buy” and see 20–30% upside over the next year, with price targets clustered around $16–$17.

Who’s Buying? Insiders, Hedge Funds, and Politicians

Here’s where things get interesting. Recently, there’s been a wave of buying from insiders and institutions:

• Big Insider Buys: A director, Thomas R. Knott, made a huge purchase—almost $10 million worth of shares. That’s not pocket change, and it’s the kind of vote of confidence that gets noticed.

• Hedge Funds: Institutional investors have been net buyers, with more funds adding to their stakes than trimming them. That’s a good sign that the “smart money” sees potential.

• Political Interest: Congressman Brad Knott (no relation to Thomas, as far as we know) jumped in with a buy earlier this year. When politicians start buying, it always raises eyebrows—sometimes they know what’s coming before the rest of us.

The Bull Case

• Growth Story: International sales are ramping up, and the Arculus digital security business could be a sleeper hit if the market keeps moving toward secure digital payments.

• Analyst Love: Wall Street is solidly behind this one, with most calling it a buy and expecting double-digit gains.

• Insider Confidence: Big insider buys are usually a bullish signal—they know the business better than anyone.

The Bear Case

• Short-Term Overvaluation?: Some technical models say the stock might be a bit ahead of itself right now, trading above short-term forecasts.

• Profitability: Still running at a loss, so there’s execution risk if growth doesn’t keep up.

• Market Sentiment: The “Fear & Greed Index” is showing some fear, and volatility is a bit high, so expect a bumpy ride.

The Bottom Line

CompoSecure is shaping up as a high-potential, higher-risk fintech play. The company’s got a real business, growing sales, and a digital security angle that could pay off big. With insiders, hedge funds, and even a congressman piling in, there’s clearly something brewing. But as always, with a stock that’s not yet profitable and has run up a lot, you’ve got to be ready for some volatility.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor before making investment decisions. Investing in stocks involves risk, including the loss of principal.